NovAccess Global Inc. reports no revenue and a net loss of $2,657,889 for the year ended September 30, 2024, narrower than its prior-year loss. The biopharmaceutical company is focused on TLR-AD1, a dendritic cell-based immunotherapy for glioblastoma, and related IDH1 biomarker technology, both still in pre-clinical and clinical development stages.
The company has suspended operations due to lack of funds, carries approximately $2.3 million of largely past-due debt, and its auditors have issued a going concern opinion. Management highlights significant dilution risk from convertible debt, preferred stock, options and warrants, and notes it is exploring financing with Vital Science Innovations. As of January 14, 2026, 61,652,385 common shares were outstanding, with a large pool of authorized but unissued shares that could be used for future financings.